Profile: Eli Lilly and Co (LLY.N)
26 Apr 2017
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Human Pharmaceutical Products
The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's endocrinology products include Humalog, Humalog Mix 75/25 and Humalog Mix 50/50, which are insulin analogs for the treatment of diabetes; Humulin, which is a human insulin of recombinant deoxyribonucleic acid (DNA) origin for the treatment of diabetes; Trajenta, which is used for the treatment of type II diabetes; Jentadueto, which is a combination tablet of linagliptin (Trajenta) and metformin hydrochloride for use in the treatment of type II diabetes; Jardiance, which is used for the treatment of type II diabetes; Trulicity, which is used for the treatment of type II diabetes; Glyxambi, which is a combination tablet of linagliptin and empagliflozin (Jardiance) for the treatment of type II diabetes; Synjardy, which is a combination tablet of empagliflozin and metformin hydrochloride for the treatment of type II diabetes; Basaglar (insulin glargine injection), which is a long-acting human insulin analog for the treatment of diabetes; Forteo, which is used for the treatment of osteoporosis in postmenopausal women and men at risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, which is used for the prevention and treatment of osteoporosis in postmenopausal women and for managing the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at risk for invasive breast cancer; Humatrope, which is used for the treatment of human growth hormone deficiency and certain pediatric growth conditions, and Axiron, which is a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The Company's neuroscience products include Cymbalta, Zyprexa, Strattera, Prozac and Amyvid. Cymbalta is used for the treatment of depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis. Zyprexa is used for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder and bipolar maintenance. Strattera is used for the treatment of attention-deficit hyperactivity disorder. Prozac is used for the treatment of depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder. Amyvid is a radioactive diagnostic agent for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline.
The Company's oncology products include Alimta, Erbitux, Cyramza, Gemzar, Portrazza and Lartruvo. Its Alimta is used for the first-line treatment, in combination with another agent, of non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of non-squamous NSCLC; as monotherapy for the maintenance treatment of non-squamous NSCLC in patients, and in combination with another agent, for the treatment of malignant pleural mesothelioma. Erbitux is indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers. It is used as a single agent, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Gemzar is used for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, advanced or recurrent ovarian cancer, and in the European Union for the treatment of bladder cancer. Cyramza is approved in the United States and the European Union both as a single agent and in combination with another agent for advanced or metastatic gastric cancer, and approved in the United States in combination with another agent as a second-line treatment of metastatic NSCLC. Portrazza is approved in the United States for use in combination with other agents as a first-line treatment of metastatic squamous NSCLC, and approved in the European Union for use in combination with other agents as a first-line treatment for epidermal growth factor receptor expressing squamous NSCLC. Lartruvo is approved in the United States and conditionally approved in the European Union, for use in combination with another agent for the treatment of soft tissue carcinoma.
The Company's immunology products include Olumiant and Taltz. Olumiant is approved in the European Union for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). Taltz is used for the treatment of moderate-to-severe plaque psoriasis (approved the United States and European Union) and psoriatic arthritis (approved in Japan). The Company's cardiovascular products include Cialis and Effient. Cialis is used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Effient is used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome, including patients undergoing angioplasty, atherectomy or stent placement.
Animal Health Products
The Company's animal health products segment includes products for food animals and products for companion animals. The Company's products for food animals include Rumensin, Coban, Maxiban, Monteban, Posilac, Optaflexx, Paylean, Tylan and Denagard. Rumensin is a cattle feed additive that controls and prevents coccidiosis. Coban, Maxiban and Monteban are anticoccidial agents that are used in poultry. Posilac is a protein supplement to manage milk productivity in dairy cows. Optaflexx and Paylean are leanness and performance enhancers for cattle and swine, respectively. Tylan is an antibiotic used to control certain diseases in cattle, swine and poultry. Denagard is an antibiotic for the control and treatment of respiratory and enteric diseases in swine and poultry.
The Company's products for companion animals include Trifexis and Comfortis. Trifexis is a monthly chewable tablet for dogs that kills fleas, prevents flea infestations, prevents heartworm disease and controls intestinal parasite infections. Comfortis is a chewable tablet that kills fleas and prevents flea infestations on dogs. Its products also include Duramune and Duramune Ultra, which are vaccines to prevent a range of infectious diseases in dogs, including canine distemper; Duramune Lyme, which is a vaccine to prevent Lyme disease in dogs; Bronchi-Shield, which is a vaccine to prevent certain bronchial infections in dogs; Fel-O-Vax, ULTRA Fel-O-Vax and Fel-O-Guard, which are vaccines to prevent a range of infectious diseases in cats, including feline leukemia, and Rabvac, which is a vaccine to prevent rabies in dogs, cats and horses.
Eli Lilly and Co
Lilly Corporate Ctr, Drop Code 1
INDIANAPOLIS IN 46285
Company Web Links
- EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
- EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
- Boehringer eyes marked sales gain, boosted by animal health
- BRIEF-Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock
- BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent